ZURA ZURA
Company Profile ↓Company Overview
ZURA (ZURA) is a publicly traded company listed on with a market capitalization of $363.25M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.08.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +124.09% |
| 6 Months: | -21.50% |
| 3 Months: | +33.97% |
| 1 Month: | -11.49% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 30.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 19.25M | 18.06M | 19.52M | 18.41M | 25.50M |
| Operating Income | -19.14K | -321.86K | -7.82M | -927.00K | -1.07M | -7.72M | -33.91M | -10.19M | -8.38M | -11.76M | -19.32M | - | -19.25M | -18.06M | -19.52M | -18.41M | -25.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -19.25M | -18.05M | -19.50M | -18.40M | -25.48M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -17.44M | -15.99M | -18.04M | -17.18M | -24.22M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -19.14K | 5.79M | 7.80M | -925.00K | -1.10M | -9.59M | -34.02M | -8.27M | -7.75M | -10.33M | -20.70M | - | -17.44M | -15.99M | -18.04M | -17.18M | -24.22M |
| Diluted EPS | - | - | -72,395.48 | -9.54 | -2.87 | -2.76 | -1.31 | -0.18 | -0.02 | -0.17 | -0.26 | - | -0.19 | -0.17 | -0.21 | - | -0.22 |
| R&D Expense | - | - | 7.50M | 85.00K | 415.00K | 4.88M | 28.23M | 3.96M | 3.59M | 5.54M | 6.03M | - | 10.47M | 8.70M | 11.95M | - | 14.75M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 27.16M | 62.64M | 55.19M | 75.25M |
| Operating Income | -27.16M | -62.64M | -55.19M | -75.25M |
| EBITDA | -27.16M | -62.64M | -55.18M | -75.20M |
| Interest Expense | - | - | - | - |
| Pretax Income | -27.33M | -60.56M | -52.40M | -68.65M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -25.74M | -60.36M | -52.40M | -68.65M |
| Diluted EPS | -12.19 | -2.09 | -0.60 | -1.06 |
| R&D Expense | 23.69M | 44.00M | 24.40M | 42.08M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2021 | Dec 2021 | Mar 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 5.26M | 100.84M | 179.53M | 113.95M |
| Current Assets | - | - | - | 1.78M | 100.84M | 178.74M | 112.31M |
| Cash & Equivalents | - | - | - | 1.57M | 99.81M | 176.50M | 109.41M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | 27.32M | 21.29M | 19.51M | 12.41M |
| Current Liabilities | - | - | - | 14.82M | 20.30M | 19.51M | 12.41M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 7.76M | - | - | - |
| Total Equity | 0 | - | - | -32.06M | 59.33M | 146.81M | 101.54M |
| Shares Outstanding | - | - | - | 27.05M | 43.59M | 65.30M | 73.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.20M | -15.05M | -28.08M | -64.81M |
| Investing Cash Flow | -12.00M | -8.00M | -5.08M | -113.00K |
| Financing Cash Flow | 14.77M | 121.29M | 109.84M | -2.16M |
| Capital Expenditure | -12.00M | -8.00M | -5.08M | -113.00K |
| Free Cash Flow | -13.20M | -23.05M | -33.15M | -64.93M |
| Net Change in Cash | 1.57M | 98.24M | 76.69M | -67.09M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 80.3% | -101.7% | -35.7% | -67.6% |
| ROCE % | 284.2% | -77.8% | -34.5% | -74.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Montanova Capital LLC | 9.85% | 9.44M | $54.01M |
| 2 | Venrock Adviser, LLC | 6.72% | 6.43M | $36.81M |
| 3 | MPM Bioimpact LLC | 4.67% | 4.47M | $25.58M |
| 4 | JPMORGAN CHASE & CO | 4.54% | 4.35M | $24.91M |
| 5 | Great Point Partners LLC | 4.40% | 4.22M | $24.12M |
| 6 | Braidwell LP | 4.15% | 3.98M | $22.77M |
| 7 | Siren, L.L.C. | 3.90% | 3.73M | $21.36M |
| 8 | Blackrock Inc. | 3.77% | 3.61M | $20.68M |
| 9 | Commodore Capital Lp | 3.39% | 3.25M | $18.59M |
| 10 | Adage Capital Partners GP L.L.C. | 2.87% | 2.75M | $15.73M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZURA
Zura Bio to Participate in the Cantor Global Healthcare Conference
HENDERSON, Nev., August 31, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating aut…
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HENDERSON, Nev., August 21, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and…
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
One Zura Bio Insider Raised Their Stake In The Previous Year
Viewing insider transactions for Zura Bio Limited's ( NASDAQ:ZURA ) over the last year, we see that insiders were net...
Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply
On August 11, Zura Bio (NASDAQ:ZURA) reported second-quarter results that landed on an unusual mix of good and bad news. The clinical-stage biotech finished enrolling two separate Phase 2 studies of its lead drug, tibulizumab, both ahead of…
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
HENDERSON, Nev., June 29, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoi…
ZURA — Frequently Asked Questions
What is the current share price of ZURA?
As of 2026-09-16 18:39 PDT, ZURA trades at $4.93 on NASDAQ/NYSE. Its 52-week range is $1.90 to $7.04.
What is the market capitalisation of ZURA?
ZURA has a market capitalisation of $363.25M on NASDAQ/NYSE.
What is the P/E ratio of ZURA?
ZURA trades at a trailing price-to-earnings (P/E) ratio of -4.65. Its price-to-book (P/B) ratio is 4.32.
What is the return on equity (ROE) of ZURA?
ZURA has a return on equity (ROE) of -67.61%. Its return on capital employed (ROCE) is -74.11%.
Is ZURA a good stock to buy?
This page provides a data-driven analysis of ZURA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.